Abionyx Pharma (XPAR:ABNX) Long-Term Capital Lease Obligation : €1.47 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Long-Term Capital Lease Obligation?

Abionyx Pharma's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.47 Mil.

Abionyx Pharma's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (€1.73 Mil) to Jun. 2023 (€1.57 Mil) and declined from Jun. 2023 (€1.57 Mil) to Dec. 2023 (€1.47 Mil).

Abionyx Pharma's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€2.25 Mil) to Dec. 2022 (€1.73 Mil) and declined from Dec. 2022 (€1.73 Mil) to Dec. 2023 (€1.47 Mil).

Abionyx Pharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Abionyx Pharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Long-Term Capital Lease Obligation Chart

Abionyx Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.02

2.25

1.73

1.47

Abionyx Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.25	2.05	1.73	1.57	1.47

Abionyx Pharma (XPAR:ABNX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Abionyx Pharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Abionyx Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

0RAG:UK 609:Germany

Address

33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130

Website

https://www.abionyx.com

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma Headlines

No Headlines